



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Altman et al.)	Group Art Unit:	1752
)		
Serial No.:	10/579,248)	Examiner:	Unknown

U.S. National Stage of PCT/US2004/037896)

International Filing Date: 12 November 2004)

For: BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Pursuant to MPEP § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Applicants also wish to bring the Examiner's attention to any pending U.S. Application cited in the 1449 form(s) submitted herewith, as well as any documents, Office Actions that may include rejections of similar claims, and any provisional U.S. patent applications referenced in the pending U.S. applications or in their file wrappers.

Information Disclosure Statement

Applicant(s): Altman et al. Serial No.: 10/579,248

International Filing Date: 12 November 2004

For: BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

By

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

"Express Mail" mailing label number:

EV201878081US

Date of Deposit: 29 December 2006

29 DECEMBER 2006 Date

By: Kathleen L. Franklin

Respectfully submitted

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

P.O. Box 581415

Mueting, Raasch & Gebhardt, P.A.

Minneapolis, MN 55458-1415

Reg. No. 47,574

Direct Dial (612)305-1873

hcant(s): FIRM PRABE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Altman et al.

Group Art Unit: 1752

rial No.:

10/579,248

Examiner: Unassigned

International Filing Date: 12 November 2004

Docket No.: 235.00550101

Title:

BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- Small entity status is entitled to be asserted in the above-identified application. X
- An itemized return postcard. X
- A Petition for Extension of Time for _ month(s). Please charge Deposit Account No. 13-4895 in the amount of \$ for the required fee.
- An Information Disclosure Statement (2 pgs), copies of 0 applications; 1449 forms (5 pgs); and copies of <u>X</u> 44 documents cited on the 1449 forms.
- An Appeal Brief. Please charge Deposit Account No. 13-4895 in the amount of \$_, for the required Appeal Brief filing fee.
- A check in the amount of \$__, representing ___.

Other: Amendment		No Additional fee is required.		The fee has been calculated as shown	
	Fee Calculation for Claims Pending After Amendment				
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$25 =	
Independent Claims				x \$100 =	
One or I	More New Multiple	Dependent Claims P	resented? If Yes	, Add \$180 Here →	
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

Name: Kathleen L. Franklin

Reg. Nov. 47,574

Direct Dial: 612-305-1873 Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:


"Express Mail" mailing label number: EV201878081US

Date of Deposit: 29 December 2006

I hereby certify that the Transmittal Letter and the paper(s) and/or fee(s), as described hereinabove, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WEBURG

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.10)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Altman et al.

Group Art Unit: 1752

10/579,248

Examiner: Unassigned

International Filing Date: 12 November 2004

Docket No.: 235.00550101

Title:

<u>X</u>

BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

X	Small entity status is entitled to be asserted in the above-identified application.
X	An itemized return postcard. A Petition for Extension of Time for month(s). Please charge Deposit Account No. 13-4895 in the
	amount of \$_ for the required fee.

An Information Disclosure Statement (2 pgs), copies of 0 applications; 1449 forms (5 pgs); and copies of 44 documents cited on the 1449 forms.

An Appeal Brief. Please charge Deposit Account No. 13-4895 in the amount of \$_, for the required Appeal Brief filing fee.

A chook in the amount of & representing

Amendm		No Additional fee is ulation for Claims			alculated as shown
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$25 =	
Independent Claims				x \$100 =	

Total Additional Claim Fees Required Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter

these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

By: Name: Kathleen L. Franklin

Reg. Nov. 47,574

Direct Dial: 612-305-1873 Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:

"Express Mail" mailing label number: EV201878081US

Date of Deposit: 29 December 2006

I hereby certify that the Transmittal Letter and the paper(s) and/or fee(s), as described hereinabove, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.10)

Applicant(s): ATTENDE FRABE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Altman et al.

Group Art Unit: 1752

rial No.:

10/579,248

Examiner: Unassigned

International Filing Date: 12 November 2004

Docket No.: 235.00550101

Title:

BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

4 7	C11 4'44	tatus is entitled to	1		[2] 12 42
X	- Amali antity cr	ratiic ic entitien to	no accerted in	THE SHAVE-IMENTII	nea anniication
4	Dinan Chut St	iaius is chilicu to	DC ASSCITCU III	uic above-iucitii	ncu appnicanon.

<u>X</u> An itemized return postcard.

A Petition for Extension of Time for _ month(s). Please charge Deposit Account No. 13-4895 in the amount of \$__ for the required fee.

<u>X</u> An Information Disclosure Statement (2 pgs), copies of 0 applications; 1449 forms (5 pgs); and copies of 44 documents cited on the 1449 forms.

An Appeal Brief. Please charge Deposit Account No. 13-4895 in the amount of \$_, for the required Appeal Brief filing fee.

A check in the amount of \$__, representing ___.

Other: ___.

No Additional fee is required. The fee has been calculated as shown: Amendment

	Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required	
Total Claims				x \$25 =		
Independent Claims				x \$100 =		
One or N	One or More New Multiple Dependent Claims Presented? If Yes, Add \$180 Here →					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

Name: Kathleen L. Franklin

Total Additional Claim Fees Required

Reg. Nov. 47,574

Direct Dial: 612-305-1873 Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:

"Express Mail" mailing label number: EV201878081US

Date of Deposit: 29 December 2006

I hereby certify that the Transmittal Letter and the paper(s) and/or fee(s), as described hereinabove, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TORBORG

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.10)

INFORMATION
DISCLOSURE
STATEMENT
IPE 49

Atty. Docket No.: 235.00550101	Serial No.: 10/579,248
Applicant(s): Altman et al.	Confirmation No.: 7812
International Filing Date: 12 Nov 20 04	Group: 1752
Information Disclosure Statement mailed:	December 29, 2006

DEC 2 9 2006

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,108,921	04/28/92	Low et al.			
	5,416,016	05/16/95	Low et al.			
	5,635,382	06/03/97	Low et al.			
	5,688,488	11/18/97	Low et al.			
	5,820,847	10/13/98	Low et al.			
	5,976,535	11/02/99	Fritzberg et al.			
	6,306,993	10/23/01	Rothbard et al.			
	6,451,971 B1	09/17/02	Akiyama et al.			
	6,495,663 B1	12/17/02	Rothbard et al.			
	6,624,140 B1	09/23/03	Abraham et al.			
, ,	2002-0131965 A1	09/19/02	Rothbard et al.			
	2003-0162719 A1	08/28/03	Rothbard et al.			
	2004-0049011 A1	03/11/04	Abraham et al.			
	2005-0136008 A1	06/23/05	Elmaleh et al.			
	2006-0111274 A1	05/25/06	Rothbard et al.			

FOREIGN PATENT DOCUMENTS

Examiner		Document Number	Date	Country	Class	Subclass	Trans	slation
Initial							Yes	No
	9	CA 2 545 679 A1 (in the family of WO 2005/046730)	05/26/05	Canada				
		EP 1 036 798 A1	09/20/00	EPO		·		
	•	EP 1 036 798 B1	07/16/03	EPO				
	•	WO 90/12096 A1	10/18/90	WIPO				

EXAMINER	Date Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	INFORMATION DISCLOSURE
01	P ESTATEMENT
DEC	2 9 2006

Atty. Docket No.: 235.00550101	Serial No.: 10/579,248
Applicant(s): Altman et al.	Confirmation No.: 7812
International Filing Date: 12 Nov 20 04	Group: 1752
Information Disclosure Statement mailed:	December 29, 2006

					_	 	
MEET	•	WO 95/31556 A1	11/23/95	WIPO			
	,	WO 98/52614 A2, A3	11/26/98	WIPO			-
	•	WO 99/06440 A1	02/11/99	WIPO			
	•	WO 2005/032598 A1	04/14/05	WIPO			
	•	WO 2005/046730 A2, A3	05/26/05	WIPO			0

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial		Document Description
	t pa	Altman et al., "S Gene Product: Identification and Membrane Localization of a Lysis Control Protein," J. Bacteriol., Sept. 1983; 155(3):1130-1137.
	73	Ames et al., "Illicit Transport: The Oligopeptide Permease," <i>Proc. Natl. Acad. Sci. USA</i> , Feb. 1973; 70(2):456-458.
	•	Ames et al., "Simple, Rapid, and Quantitative Release of Periplasmic Proteins by Chloroform," <i>J. Bacteriol.</i> , Dec. 1984; <i>160</i> (3):1181-1183.
	•	Atherton et al., "Phosphonopeptide Antibacterial Agents Related to Alafosfalin: Design, Synthesis, and Structure-Activity Relationships," <i>Antimicrob. Agents and Chemother.</i> , Dec. 1980; 18(6):897-905.
	9	Barak et al., "Specialized Peptide Transport System in <i>Escherichia coli</i> ," <i>J. Bact.</i> , June 1975; <i>122</i> (3):1200-1207.
	•	Bodanszky et al., "Synthesis of Biocytin-Containing Peptides," J. Am. Chem. Soc., Jan. 1977; 99(1):235-239.
		Bonfils et al., "Uptake by Macrophages of a Biotinylated Oligo-α-deoxythymidylate by Using Mannosylated Streptavidin," <i>Bioconjug. Chem.</i> , July-Aug. 1992; <i>3</i> (4):277-284.
	1	Campbell, "Sensitive Mutants of Bacteriophage λ," <i>Virology</i> , May 1961; <i>14</i> :22-32.
	•	Campbell et al., "A Mutant of <i>Escherichia coli</i> That Requires High Concentrations of Biotin," <i>Proc. Nat. Acad. Sci. USA</i> , March 1972; 69(3):676-680.

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next	,

INFORMATION
DISCLOSURE
STATEMENT

Serial No.: 10/579,248
Confirmation No.: 7812
Group: 1752

DEC 2 9 2006

Information Disclosure Statement mailed: December 29, 2006

<u> </u>	20/	
Beaminer Fri (ABE)	Part of A	Document Description
	6-	Campbell et al., "Biotin Regulatory (bir) Mutations of Escherichia coli," J. Bacteriol., June 1980; 142(3)1025-1028.
	(Chen et al, "Increased Cellular Uptake of the Human Immunodeficiency Virus-1 Tat Protein after Modification with Biotin," <i>Analytical Biochemistry</i> , May 1995; 227:168-175.
		Dargis et al., "Use of Biotinylated β-Lactams and Chemiluminescence for Study and Purification of Penicillin-Binding Proteins in Bacteria," <i>Antimicrobial Agents and Chemotherapy</i> , May 1994; <i>38</i> (5):973-980.
	•	Detmers et al., "Kinetics and Specificity of Peptide Uptake by the Oligopeptide Transport System of <i>Lactococcus lactis</i> ," <i>Biochemistry</i> , Nov. 1998; <i>37</i> :16671-16679.
		Eisenberg et al., "Properties of α-Dehydrobiotin-Resistant Mutants of Escherichia coli K-12," J. Bacteriol., Apr. 1975; 122(1):66-72.
	•	Fall et al., "Analysis of bacterial biotin-proteins," <i>Biochim. Biophys. Acta</i> , Feb. 1975; <i>379</i> (2):496-503.
		Gilleland, Jr., et al., "Ultrastructural and Chemical Alteration of the Cell Envelope of <i>Pseudomonas aeruginosa</i> , Associated with Resistance to Ethylenediaminetetraacetate Resulting from Growth in a Mg ²⁺ -Deficient Medium," <i>J. Bacteriol.</i> , Jan. 1974; 117(1):302-311.
		Green, "Avidin 3. The Nature of the Biotin-Binding Site," <i>Biochem. Journal</i> , Dec. 1963; 89(3):599-609.
	٤	Guha, "Divergent Orientation of Transcription from the Biotin Locus of Escherichia coli," J. Mol. Biol., Feb. 1971; 56:53-62.
		Hofmann et al., "Avidin-Biotin Affinity Columns. General Methods for Attaching Biotin to Peptides and Proteins," <i>J. Am. Chem. Soc.</i> , May 1978; 100(11):3585-3590.
		Ketner et al., "A Deletion Mutation Placing the Galactokinase Gene of <i>Escherichia coli</i> under Control of the Biotin Promoter," <i>Proc. Natl. Acad. Sci. USA</i> , July 1974; 71(7):2698-2702.

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not conformance and not considered. Include copy of this form	citation is in conformance with MPEP 609; Draw line through citation if not in m with next communication to applicant.

INFORMATION
DISCLOSURE
STATEMENT
OIPE

Atty. Docket No.: 235.00550101	Serial No.: 10/579,248
Applicant(s): Altman et al.	Confirmation No.: 7812
International Filing Date: 12 Nov 20 04	Group: 1752

DEC 2 9 2006 8

Information Disclosure Statement mailed: December 29, 2006

Example Market	Document Description
	Kinoshita et al., "Proton Motive Force Is Not Obligatory for Growth of <i>Escherichia coli</i> ," <i>J. Bacteriol</i> ., Dec. 1984; <i>160</i> (3):1074-1077.
	Luckey et al., "Iron Uptake in Salmonella typhimurium: Utilization of Exogenous Siderochromes as Iron Carriers," J. Bacteriol., Sept. 1972; 111(3):731-738.
	Mah et al., "Nutritional Requirements of <i>Staphylococcus aureus</i> S-6," <i>Appl. Microbiol.</i> , July 1967; <i>15</i> (4):866-870.
	Minko et al., "Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells," <i>Cancer Chemother. Pharmacol.</i> , Aug. 2002; 50:143-50. Available on-line June 11, 2002.
	Naider et al., "Multiplicity of Oligopeptide Transport Systems in <i>Escherichia coli</i> ," <i>J. Bacteriol</i> ., June 1975; <i>122</i> (3):1208-1215.
	Nikaido et al., "Molecular Basis of Bacterial Outer Membrane Permeability," <i>Microbiol Rev.</i> , Mar. 1985; 49(1):1-32.
	Nikaido, "Chapter 5: Outer Membrane," in <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i> , 2 nd ed., Vol. 1., ASM Press, American Society for Microbiology, Washington, D.C. 1996, Title page, publication page and pages 29-47.
	NNIS System Report, Special Articles, "National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002," Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, GA, November 2002, pages 458-475.
	Otvos, Jr. et al., "Interaction between Heat Shock Proteins and Antimicrobial Peptides," <i>Biochemistry</i> , Nov. 2000; <i>39</i> (46):14150-14159. Available on-line October 21, 2000.
	Pai, "Biotin uptake in Biotin Regulatory Mutant of <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , Oct. 1973; <i>116</i> (1):494-496.
	Pardridge, "Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier," <i>Arch. Neurol.</i> , Jan. 2002; 59:35-40.

EXAMINER Date Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION
DISCLOSURE
STATEMENT
OIPE

Atty. Docket No.: 235.00550101	Serial No.: 10/579,248
Applicant(s): Altman et al.	Confirmation No.: 7812
International Filing Date: 12 Nov 20 04	Group: 1752
Information Disclosure Statement mailed:	December 29, 2006

DEC 2 9 2006 8

THE PARTY OF THE P	Document Description
	Payne et al., "Size Restriction on Peptide Utilization in Escherichia coli," J. Biol. Chem, Dec. 1968; 243(23):6291-6299.
	Ramanathan et al., "Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide," <i>J. Control. Release</i> , Dec. 2001; 77(3):199-212.
	Stolz et al., "Rapid purification of a functionally active plant sucrose carrier from transgenic yeast using a bacterial biotin acceptor domain," <i>FEBS Letters</i> , 1995; 377:167-171.
	Wermuth et al., "Glossary of Terms used in Medicinal Chemistry (IUPAC Recommendations 1998)," [online]. International Union of Pure and Applied Chemistry, Chemistry and Human Health Division, Medicinal Chemistry Section (1998). [retrieved on 2006-10-05]. Retrieved from the Internet: <url:www.chem.qmul.ac.uk iupac="" medchem="">; 2 pgs.</url:www.chem.qmul.ac.uk>

EXAMINER	Date Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.